A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

Anders* Bach; Bettina H Clausen; Magda Møller; Bente Vestergaard; Celestine N Chi; Adam Round; Pernille Louise Sørensen; Klaus Bertram Nissen; Jette Sandholm Kastrup; Michael Gajhede; Per Jemth; Anders Skov Kristensen; Patrik Lundström; Kate Lykke Lambertsen; Kristian* (*Corresponding) Strømgaard

doi:10.1073/pnas.1113761109

A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

Anders* Bach, Bettina H Clausen, Magda Møller, Bente Vestergaard, Celestine N Chi, Adam Round, Pernille Louise Sørensen, Klaus Bertram Nissen, Jette Sandholm Kastrup, Michael Gajhede, Per Jemth, Anders Skov Kristensen, Patrik Lundström, Kate Lykke Lambertsen, Kristian* (*Corresponding) Strømgaard

118 Citations (Scopus)

Abstract

Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-d-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.

Original language	English
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	109
Issue number	9
Pages (from-to)	3317-3322
ISSN	0027-8424
DOIs	https://doi.org/10.1073/pnas.1113761109
Publication status	Published - 28 Feb 2012

Access to Document

10.1073/pnas.1113761109

Cite this

Bach, A., Clausen, B. H., Møller, M., Vestergaard, B., Chi, C. N., Round, A., Sørensen, P. L., Nissen, K. B., Kastrup, J. S., Gajhede, M., Jemth, P., Kristensen, A. S., Lundström, P., Lambertsen, K. L., & Strømgaard, K. C. (2012). A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proceedings of the National Academy of Sciences of the United States of America, 109(9), 3317-3322. https://doi.org/10.1073/pnas.1113761109

A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. / Bach, Anders*; Clausen, Bettina H; Møller, Magda et al.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 9, 28.02.2012, p. 3317-3322.

Research output: Contribution to journal › Journal article › Research › peer-review

Bach, A, Clausen, BH, Møller, M, Vestergaard, B, Chi, CN, Round, A, Sørensen, PL, Nissen, KB, Kastrup, JS , Gajhede, M, Jemth, P, Kristensen, AS, Lundström, P, Lambertsen, KL & Strømgaard, KC 2012, 'A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage', Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3317-3322. https://doi.org/10.1073/pnas.1113761109

@article{e7bef3927d2b49dea76046154795bb3c,

title = "A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage",

abstract = "Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-d-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.",

author = "Anders* Bach and Clausen, {Bettina H} and Magda M{\o}ller and Bente Vestergaard and Chi, {Celestine N} and Adam Round and S{\o}rensen, {Pernille Louise} and Nissen, {Klaus Bertram} and Kastrup, {Jette Sandholm} and Michael Gajhede and Per Jemth and Kristensen, {Anders Skov} and Patrik Lundstr{\"o}m and Lambertsen, {Kate Lykke} and Str{\o}mgaard, {Kristian* (*Corresponding)}",

note = "Keywords: drug discovery; ischemic stroke; protein-protein interactions",

year = "2012",

month = feb,

day = "28",

doi = "10.1073/pnas.1113761109",

language = "English",

volume = "109",

pages = "3317--3322",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "The National Academy of Sciences of the United States of America",

number = "9",

}

TY - JOUR

T1 - A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

AU - Bach, Anders

AU - Clausen, Bettina H

AU - Møller, Magda

AU - Vestergaard, Bente

AU - Chi, Celestine N

AU - Round, Adam

AU - Sørensen, Pernille Louise

AU - Nissen, Klaus Bertram

AU - Kastrup, Jette Sandholm

AU - Gajhede, Michael

AU - Jemth, Per

AU - Kristensen, Anders Skov

AU - Lundström, Patrik

AU - Lambertsen, Kate Lykke

AU - Strømgaard, Kristian (Corresponding)

N1 - Keywords: drug discovery; ischemic stroke; protein-protein interactions

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-d-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.

AB - Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-d-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.

U2 - 10.1073/pnas.1113761109

DO - 10.1073/pnas.1113761109

M3 - Journal article

C2 - 22343531

SN - 0027-8424

VL - 109

SP - 3317

EP - 3322

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 9

ER -

A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

Abstract

Access to Document

Fingerprint

Cite this